Read our SOPHiA DDM™️ Dx ROS performance evaluation study and make confident data-driven decisions that improve patient care.
Studies show that as few as 10% of people living with familial hypercholesterolemia (FH) could be aware of their diagnosis. Could genetic testing expedite early diagnosis and timely treatment?
Last week we attended the European Society for Medical Oncology (ESMO) Congress 2022, gathering the world’s leading oncologists. Read our summary of three presentations illustrating cancer therapy development.
Whole exome sequencing can present a goldilocks option between targeted gene panels and whole genome sequencing. Dive into some of the considerations for adopting whole exome sequencing in your institution.
Read about our successful collaborations, Dr Terracciano’s favorite SOPHiA DDM™ features, and what she sees in the future for SOPHiA GENETICS.
Check out our step-by-step guide to using SOPHiA DDM™️ complemented by Alamut™️ Visual Plus to streamline the interpretation of clinical exome data for neurological disorders.
Cancer management outcomes can strongly benefit from robust and accurate detection of gene fusions. SOPHiA GENETICS developed the SOPHiA DDM Dx RNAtarget Oncology Solution to make this possible.
We list 7 reasons to consider SOPHiA DDM Dx RNAtarget Oncology Solution for your assays.
Last week we attended the 2022 American Society of Clinical Oncology (ASCO) meeting, gathering the world’s leading researchers in oncology. Read our summary of four groundbreaking presentations on breast cancer research.
Read our summary of new research studies presented at the European Society of Human Genetics (ESHG) Annual Conference 2022 about how next-generation sequencing is advancing pediatric healthcare.
Test your knowledge in our quick-fire quiz for Rare Chromosome Disorder Awareness Week 2022!
Learn about the SOPHiA DDM Platform’s CNV detection algorithm from our Senior Algorithm Researcher, Bita Khalili.
Q&A with the Clinical Application Product Manager, Mikhail Pertziger, PhD